<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03855332</url>
  </required_header>
  <id_info>
    <org_study_id>13891</org_study_id>
    <secondary_id>206589/Z/17/Z</secondary_id>
    <nct_id>NCT03855332</nct_id>
  </id_info>
  <brief_title>Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial</brief_title>
  <acronym>OxHARP</acronym>
  <official_title>Oxford Haemodynamic Adaptation to Reduce Pulsatility: Randomised, Placebo-controlled, Double-blind Crossover Trial of Effects of Sildenafil on Cerebral Arterial Pulsatility in Patients With Cryptogenic or Lacunar Stroke and Small Vessel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic damage to small blood vessels deep in the brain is seen in half of patients over the&#xD;
      age of 60 and almost all patients over the age of 80, and is responsible for up to a third of&#xD;
      strokes and almost half of patients with dementia. However, there is limited evidence for how&#xD;
      small vessel disease develops and no specific treatment. One potential explanation is that&#xD;
      greater pulsations in blood pressure are transmitted to the brain through stiff blood&#xD;
      vessels, resulting in increased pressure hitting the brain each time the heart beats and&#xD;
      reduced blood flow between heart beats.&#xD;
&#xD;
      Sildenafil is used to open up blood vessels (a vasodilator) in patients with erectile&#xD;
      difficulties or poor blood supply to the lungs. This trial will test sildenafil (50mg, thrice&#xD;
      daily) against placebo and a similar drug (cilostazol 100mg, twice daily) in 75 patients with&#xD;
      previous stroke or mini-stroke and small vessel disease, given in random order to every&#xD;
      participant for 3 weeks each. It will primarily assess changes in pulsations of blood flow to&#xD;
      the brain on each tablet, measured with an ultrasound scanner (transcranial ultrasound). To&#xD;
      understand why any changes occur, we will also measure the stiffness of arteries, the blood&#xD;
      pressure at the heart and how much blood vessels in the brain open up when participants&#xD;
      breathe air with added carbon dioxide (6%), using ultrasound in all participants and on MRI&#xD;
      brain scans in 30 patients.&#xD;
&#xD;
      This study will test whether a vasodilator used in other conditions with a good safety&#xD;
      profile can reduce pulsations in blood flow to the brain, to assess whether it is a good&#xD;
      candidate drug to reduce the progression of small vessel disease in future clinical trials.&#xD;
      This would be the first effective treatment for a condition associated with a very high&#xD;
      burden of disability.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomised, double-blind, placebo and active controlled, crossover design</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Middle cerebral arterial pulsatility index</measure>
    <time_frame>3 weeks</time_frame>
    <description>Difference in Gosling's pulsatility index after three weeks treatment with sildenafil versus placebo, in 75 patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage increase in MCA velocity on 6% CO2 vs medical air</measure>
    <time_frame>3 weeks</time_frame>
    <description>Difference in cerebrovascular reactivity after 3 weeks of treatment with sildenafil versus placebo in 75 patients: cereborovascular reactivity calculated by the percentage increase in mean MCA velocity whilst breathing 6% CO2 compared to breathing medical air.&#xD;
Non-inferiority of 3 weeks of treatment with cilostazol 100mg bd compared to sildenafil 50mg tds for difference in Gosling's pulsatility index and cerebrovascular reactivity to 6% CO2.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reactivity of BOLD signal on MRI to 6% CO2 challenge</measure>
    <time_frame>3 weeks</time_frame>
    <description>Difference in cerebrovascular reactivity after 3 weeks of treatment with sildenafil versus placebo in 30 patients: cerebrovascular reactivity calculated by the percentage increase in BOLD signal on MRI whilst breathing 6% CO2 compared to breathing medical air.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Small Vessel Cerebrovascular Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All participants will undergo three phases in random order:&#xD;
The placebo phase will include overencapsulated placebo, matched to overencapsulated active agents, 2 tablets 3 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg three times daily, overencapsulated tablet, increased after 1 week to 50mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg bd, overencapsulated tablet (with midday placebo), increased after 1 week to 100mg bd (with midday placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>See above</description>
    <arm_group_label>Sildenafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>See above</description>
    <arm_group_label>Cilostazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Overencapsulated placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is willing and able to give informed consent for participation in the&#xD;
             study.&#xD;
&#xD;
          -  Male or Female, aged 18 years or above.&#xD;
&#xD;
          -  Can record MCA waveform on at least one side ('useable TCD window')&#xD;
&#xD;
          -  Non-disabling, ischaemic stroke or TIA, &gt;1 month prior to randomisation, of either&#xD;
             cryptogenic or lacunar aetiology, confirmed clinically or on brain imaging&#xD;
&#xD;
          -  White matter hyperintensities on MRI (Fazekas scale) or CT (Blennow scale) consistent&#xD;
             with cerebral small vessel disease&#xD;
&#xD;
          -  Age below 60 MRI Fazekas score 1 to 3 (max 2 points in periventricular or deep score)&#xD;
             or CT Blennow score 1 to 3 (max 2 points in periventricular or deep score)&#xD;
&#xD;
          -  Age above 60 MRI Fazekas score 1 to 4 (max 2 points in periventricular or deep score)&#xD;
             or CT Blennow score 1 to 4 (max 2 points in periventricular or deep score)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women, women of childbearing age not taking contraception.&#xD;
&#xD;
          -  Other major neurological or psychiatric conditions affecting the brain and interfering&#xD;
             with the study design (e.g. multiple sclerosis)&#xD;
&#xD;
          -  Other causes of stroke such as&#xD;
&#xD;
               -  â‰¥50% luminal stenosis (NASCET) in large arteries supplying the infarct area&#xD;
&#xD;
               -  major-risk cardioembolic source of embolism (permanent or paroxysmal atrial&#xD;
                  fibrillation, sustained atrial flutter, intracardiac thrombus, prosthetic cardiac&#xD;
                  valve, atrial myxoma or other cardiac tumours, mitral stenosis, recent (&lt;4 weeks)&#xD;
                  myocardial infarction, left ventricular ejection fraction less than 30%, valvular&#xD;
                  vegetations, or infective endocarditis)&#xD;
&#xD;
               -  other specific causes of stroke (e.g. arteritis, dissection, drug misuse)&#xD;
&#xD;
          -  Large vessel occlusion on MRA or CTA (carotid, basilar or MCA)&#xD;
&#xD;
          -  Modified Rankin Score &gt;3&#xD;
&#xD;
          -  Unable to swallow&#xD;
&#xD;
          -  Renal impairment (eGFR &lt;35ml/min)&#xD;
&#xD;
          -  Significant biochemical abnormalities (sodium &lt;130, K+ &lt;2.5 or &gt;5.5, LFTs &gt;3 x upper&#xD;
             limit of normal range)&#xD;
&#xD;
          -  Life expectancy &lt;2 years&#xD;
&#xD;
          -  Contraindication to active agents&#xD;
&#xD;
               -  Concurrent use of alphablocker&#xD;
&#xD;
               -  Regular use of nitrate (ISMN, GTN, other)&#xD;
&#xD;
               -  Heart failure (NYHA 2-4)&#xD;
&#xD;
               -  Severe aortic stenosis&#xD;
&#xD;
               -  Bilateral renal artery stenosis&#xD;
&#xD;
               -  Uncontrolled arrhythmias&#xD;
&#xD;
               -  Previous priapism&#xD;
&#xD;
               -  Anatomical deformation of the penis&#xD;
&#xD;
               -  Recent myocardial infarction (within 6 months)&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  History of non-arteritic ischaemic optic neuropathy&#xD;
&#xD;
               -  Hypotension: BP &lt;90/60&#xD;
&#xD;
               -  Haemodynamically significant aortic / mitral valve disease&#xD;
&#xD;
               -  Sickle cell disease, myeloma, leukaemia&#xD;
&#xD;
               -  Uncontrolled hypertension (BP &gt;180/110 despite treatment with 3&#xD;
                  antihypertensives)&#xD;
&#xD;
          -  Scheduled elective surgery or other procedures requiring general anaesthesia during&#xD;
             the study.&#xD;
&#xD;
          -  Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may either put the participants at risk because of participation in the study or the&#xD;
             participant's ability to participate in the study.&#xD;
&#xD;
          -  Participants who have participated in another research study involving an&#xD;
             investigational product in the past 12 weeks.&#xD;
&#xD;
          -  Use of an anticoagulant (warfarin, dabigatran, rivaroxaban etc) or more than one&#xD;
             antiplatelet drug.&#xD;
&#xD;
          -  Predisposition to intracerebral haemorrhage (previous ICH, likely cerebral amyloid&#xD;
             angiopathy) or intraocular haemorrhage (uncontrolled diabetic retinopathy or&#xD;
             neovascularisation)&#xD;
&#xD;
          -  Allergy to constituents of medications or components of placebo / overencapsulation&#xD;
&#xD;
          -  Use of CYP inducers that interact with study medications (ketoconazole, erythromycin).&#xD;
&#xD;
        Exclusion criteria specific for MRI substudy&#xD;
&#xD;
          -  Not able to transfer to MRI scanner&#xD;
&#xD;
          -  Active respiratory illness (such as moderate to severe asthma or COPD) such that they&#xD;
             are unable to tolerate MRI or unable to lie flat&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Contraindication to MRI scan (pacemaker, aneurysm clip etc)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr A Webb, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr A Webb, DPhil</last_name>
    <phone>+441865231601</phone>
    <email>alastair.webb@ndcn.ox.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <state>Oxon</state>
        <zip>OX39DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alastair Webb, DPhil</last_name>
      <phone>+441865231601</phone>
      <email>alastair.webb@ndcn.ox.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Cerebral Small Vessel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This will be determined on specific request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

